Polymorphisms in CCL5 promoter are associated with pulmonary tuberculosis in northern Spain

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 4, 2009, Pages 480-485

  Sanchez Castanon M ^a   Baquero, I C ^a   Sanchez Velasco P ^a   Farinas M C ^a   Ausin F ^a   Leyva Cobian F ^a   Ocejo Vinyals, J G ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Allele; CCL chemo Kine; Polymorphism; Pulmonary tuberculosis; Susceptibility

Indexed keywords

RANTES;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ALLELES; CHEMOKINE CCL5; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SPAIN; TUBERCULOSIS, PULMONARY;

EID: 64549147528     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/ TB/2007.376. Geneva, Switzerland: WHO, 2007.
2. Diez M, Huerta C, Moreno T, et al., for the Multicentre Project for Tuberculosis Research MPTR Study Group. Tuberculosis in Spain: epidemiological pattern and clinical practice. Int J Tuberc Lung Dis 2002; 6: 295-300.
3. Rodriguez-Valfn E. Current situation of respiratory tuberculosis in Spain. Euro Surveill 2002; 6: 2114.
4. Selvaraj P. Host genetics and tuberculosis susceptibility. Curr Science 2004; 86: 115-121.
5. Ogus AC, Yoldas B, Ozdemir T, et al. The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219-223.
6. Flores-Villanueva P O, Ruiz-Morales J A, Song C H, et al. A functional promoter polymorphism in monocyte chemoattrac- tant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med 2005; 202: 1649-1658.
7. Bellamy R. Genome-wide approaches to identifying genetic factors in host susceptibility to tuberculosis. Microbes Infect 2006; 8: 1119-1123.
8. Oh J H, Yang C S, Noh Y K, et al. Polymorphisms of interleukin- 10 and tumour necrosis factor-α genes are associated with newly diagnosed and recurrent pulmonary tuberculosis. Respirology 2007; 12: 594-598.
9. Hwang J H, Kim E J, Kim S Y, et al. Polymorphisms of inter- feron-γ and interferon--γ receptor 1 genes and pulmonary tuberculosis in Koreans. Respirology 2007; 12: 906-910.
10. Luster A D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
11. Gerard C, Rollins B J. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
12. Taub D D, Turcovski-Corrales S M, Key M L, Longo D L, Murphy W J. Chemokines and T-lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156: 2095-2103.
13. Bacon K B, Premack B A, Gardner P, Schall T J. Activation of dual t-cell signaling pathways by the chemokine CCL5. Science 1995; 269: 1727-1730.
14. Wong M M, Fish E N. Chemokines: attractive mediators of the immune response. Semin Immunol 2003; 15: 5-14.
15. Lima M F, Zhang Y, Villalta F. Beta-chemokines that inhibit HIV-1 infection of human macrophages stimulate uptake and promote destruction of Trypanosoma cruzi by human macrophages. Cell Mol Biol (Noisy-le-Grand) 1997; 43: 1067- 1076.
16. Chensue S W, Warmington K S, Allenspach E J, et al. Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen- elicited granulomatous inflammation. J Immunol 1999; 163: 165-173.
17. Saukkonen J J, Bazydlo B, Thomas M, Strieter R M, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun 2002; 70: 1684-1693.
18. Nickel R G, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine CCL5. J Immunol 2000; 164: 1612-1616.
19. Liu H, Chao D, Nakayama E E, et al. Polymorphism in CCL5 chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999; 96: 4581-4585.
20. An P, Nelson G W, Wang L, et al. Modulating influence on HIV/ AIDS by interacting CCL5 gene variants. Proc Natl Acad Sci USA 2002; 99: 10002-10007.
21. McDermott D H, Beecroft M J, Kleeberger C A, et al. Chemokine CCL5 promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000; 14: 2671-2678.
22. Zhernakova A, Alizadeh B Z, Eerligh P H, et al. Genetic variants of CCL5 are associated with serum CCL5 level and protection for type 1 diabetes. Genes Immun 2006; 7: 544-549.
23. Chu S F, Tam C M, Wong H S, Kam K M, Lau Y L, Chiang A K S. Association between CCL5 functional polymorphisms and tuberculosis in Hong Kong Chinese. Genes Immun 2007; 8: 475-479.
24. Esteban E, Dugoujon J M, Guitard E, et al. Genetic diversity in northern Spain (Basque country and Cantabria): GM and KM variation related to demographic histories. Eur J Hum Genet 1998; 6: 315-324.
25. Sanchez-Velasco P, Gómez-Casado E, Martínez-Laso J, et al. HLA alleles in isolated populations from North Spain: origin of the Basques and the ancient Iberians. Tissue Antigens 2003; 61: 384-392.
26. Maca-Meyer N, Sanchez-Velasco P, Flores C, et al. Y chromosome and mitochondrial DNA characterization of Pasiegos, a human isolate from Cantabria (Spain). Ann Hum Genet. 2003; 67: 329-339.
27. Szalai C, Duba J, Prohászka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158: 233-239.
28. Sole X, Guino E, Vails J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929.
29. Yoo J H, Seo B H, Kim Y S. SNPAnalyzer: a web-based integrated workbench for single-nucleotide polymorphism analysis. Nucleic Acids Res 2005; 33: W483-W488.
30. Dupont W D, Plummer W D. Power and sample size calculations: a review and computer program. Controlled Clinical Trials 1990; 11: 116-128.
31. Jang Y, Chae J S, Hyun Y J, et al. The RANTES -403G>A promoter polymorphism in Korean men: association with serum RANTES concentration and coronary artery disease. Clin Sci (London) 2007; 113: 349-356.
32. Jamieson S E, Miller E N, Black G F, et al. Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazilians. Genes Immun 2004; 5: 46-57.
33. Hizawa N, Makita H, Nasuhara Y, et al. Functional single nucleotide polymorphisms of the CCL5 gene and nonemphyse- matous phenotype in COPD patients. Eur Respir J 2008; 32: 372-378.